Scott Ravech will continue as CEO with global oversight of the newly combined company, but Steen Andersen, Bifodan’s CEO has been named president of Deerland Probiotics and Enyzmes International.
Photo © iStockphoto.com
Deerland Probiotics and Enzymes (Kennesaw, GA) has acquired Bifodan A/S (Hundested, Denmark), expanding its global footprint. A life science company specializing in developing, manufacturing, and distributing probiotic product solutions as private label dietary supplements, medical devices, and over the counter drugs, Bifodan is now a wholly owned subsidiary of Deerland.
Scott Ravech will continue as CEO with global oversight of the newly combined company, but Steen Andersen, Bifodan’s CEO has been named president of Deerland Probiotics and Enyzmes International. Andersen will be responsible for the Hundested site and all activities outside the Americas.
“We believe this investment will allow us to bring even greater value to our respective customers and to the enzyme and probiotic industries we serve,” said Ravech, in a press release. “Deerland and Bifodan are leaders in their respective markets. Bringing together this expertise will benefit both companies, our employees, and our customers.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.